Corvus Pharmaceuticals reported new Phase 1 data in atopic dermatitis that sent its stock price up by as much as 35% ...

Lan­theus fi­nal­ly came clean about the fate of its ex­per­i­men­tal ra­dio­phar­ma­ceu­ti­cal for prostate can­cer, ...

Boston-based Verastem Oncology on Thursday won accelerated approval from the FDA for Avmapki Fakzynja as a second-line ...

Takeda revealed a handful of pipeline cuts in its fourth-quarter earnings results on Thursday, as the company focuses its ...

Illumina on Thursday said the SEC has closed its investigation into the company's $8 billion purchase of Grail and doesn't ...

AstraZeneca lost its challenge to Medicare drug price negotiations in the first appeals court ruling on the merits of the ...

Illumina estimates about $85 million in costs this year related to tariffs on its DNA sequencing products, the company said ...

Vor Bio, founded by famed cancer biologist Siddhartha Mukherjee, is looking for a way out. Its decision to pursue strategic ...

The FDA is still reviewing a label expansion for GSK’s respiratory drug Nucala in chronic obstructive pulmonary disease ...

After working off $20 million in seed funding for about four years, HAYA Therapeutics tapped the funding well and came back ...

Fyodor Urnov and Kiran Musunuru advocate for streamlined CRISPR treatments for rare genetic diseases, partnering with Danaher ...

BMS commits $40B for US expansion, Shionogi buys Torii Pharma for $1.05B, Bavarian Nordic extends BARDA deal, multiple ...